Clustering of haemostatic variables and the effect of high cashew and walnut diets on these variables in metabolic syndrome patients

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 6, 2005, Pages 429-437

  Pieters, Marlien ^a   Oosthuizen, Welma ^a   Jerling, Johann C ^a   Loots, Du Toit ^a   Mukuddem Petersen, Janine ^a   Hanekom, Susanna M ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Cashews; Clustering; Coronary heart disease risk factors; Haemostasis; Insulin resistance; Metabolic syndrome; Walnuts

Indexed keywords

BLOOD CLOTTING FACTOR 7; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

ARTICLE; CARDIOVASCULAR RISK; CASHEW NUT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; FACTORIAL ANALYSIS; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MULTIPLE REGRESSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WALNUT; WEIGHT REDUCTION;

EID: 24044477228     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000174966.86549.27     Document Type: Article

References (42)

1. Juhan-Vague I, Morange PE, Alessi MC. The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Thromb 2002; 32:269-273.
2. Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly 2002; 132:241-252.
3. Isomaa B. A major health hazard: The metabolic syndrome. Life Sci 2003; 73:2395-2411.
4. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor-1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34:457-462.
5. Mertens I, van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 3:85-101.
6. Riccardi G, Rivellese AA. Dietary treatment of the metabolic syndrome - the optimal diet. Br J Nutr 2000; 83:3143-8148.
7. Fraser GE, Sabate J, Beeson WL, Strahan TM. A possible protective effect of nut consumption on risk of coronary heart disease. The Adventist Health Study. Arch Intern Med 1992; 152:1416-1423.
8. Hu FB, Stampfer MJ, Manson JE, Rimm EB, Colditz GA, Rosner BA, et al. Frequent nut consumption and risk of coronary heart disease in women: prospective cohort study. BMJ 1998; 317:1341-1345.
9. Macfarlane BJ, Bezwoda WR, Bothwell TH, Baynes RD, Bothwell JE, MacPhail AP, et al. Inhibitory effect of nuts on iron absorption. Am J Clin Nutr 1988; 47:270-274.
10. Nijveldt RJ, Van Nood E, Van Hoorn DEC, Boelens PG, Van Norren K, Van Leeuwen PAM. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 2001; 74:418-425.
11. Cooke JP, Tsao P, Singer A, Wang BY, Kosek J, Drexler H. Anti-atherogenic effect of nuts: is the answer NO? Arch Intern Med 1993; 153:898-899.
12. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins. From bench to bedside. Arterioscler Thromb Vasc Biol 2003; 23:1724-1731.
13. Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res 2002; 4:R12.
14. Grundy SM, Brewer B, Cleeman JI, Smith SC, Lenfant C, for the Conference Participants. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109:433-438.
15. Langenhoven ML, Kruger M, Gouws E, Faber M. MRC food composition tables, 3rd edition. Parow: National Research Institute for Nutritional Diseases of the South African Medical Research Council; 2001.
16. Kruger HS, Venter CS, Steyn HS. A standardized physical activity questionnaire for a population in transition: the THUSA study. Afr J Physical Health Educat Recreation Dance 2004; 6:54-64.
17. Van Jaarsveld PJ, Smuts CM, Tichelaar HY, Kruger M, Benade AJ. Effect of palm oil on plasma lipoprotein concentration and plasma low-density lipoprotein composition in non-human primates. Int J Food Sci Nutr 2000; 51:S21-S30.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
19. Katz A, Nambi SS, Mather K, Baron AD, Follman DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85:2402-2410.
20. Vorster H, Jerling J, Oosthuizen W, Cummings J, Bingham S, Magee L, et al. Tea drinking and haemostasis: a randomized, placebo-controlled, crossover study in free-living subjects. Haemostasis 1996; 26:58-64.
21. Morgan JM, Horton K, Reese D, Carey C, Walker K, Capuzzi DM. Effects of walnut consumption as part of a low-fat, low-cholesterol diet on serum cardiovascular risk factors. Int J Vitam Nutr Res 2002; 72:341-347.
22. Ros E, Nuñez I, Pérez-Heras A, Serra M, Gilabert R, Casals E, et al. A walnut diet improves endothelial function in hypercholesterolemic subjects. Circulation 2003; 109:1609-1614.
23. Brown AA, Hu FB. Dietary modulation of endothelial function: implications for cardiovascular disease. Am J Clin Nutr 2001; 73:673-686.
24. West SG. Effect of diet on vascular reactivity: an emergin marker for vascular risk. Curr Atheroscler Rep 2001; 3:446-455.
25. Kris-Etherton PM, Zhao G, Binkoski AE, Coval SM, Etherton TD. The effects of nuts on coronary heart disease risk. Nutr Rev 2001; 59:103-111.
26. Agewall S, Bokemark L, Wikstrand J, Lindahl A, Fagerberb B. Insulin sensitivity and hemostatic factors in clinically healthy 58-year-old men. Thromb Haemost 2000; 84:571-575.
27. Romano M, Guagnano MT, Pacini G, Vigneri S, Falco A, Marinopiccoli M, et al. Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab 2003; 88:5321-5326.
28. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 2002; 25:899-904.
29. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152:897-907.
30. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor-1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46:860-867.
31. Nilsson TK, Boman K, Bjerle P, Hallmans G, Hellsten G. von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Intern Med 1994; 235:419-423.
32. Marques-Vidal P, Mazoyer E, Bongard V, Gourdy P, Ruidavets JB, Drouet L, et al. Prevalence of insulin resistance syndrome in Southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 2002; 25:1371-1377.
33. Juhan-Vague I, Thompson SG, Jespersen J, on behalf of the ECAT Angina Pectoris Study Group. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb 1993; 13:1865-1873.
34. Agewall S. Insulin sensitivity and haemostatic factors in men at high and low cardiovascular risk. J Intern Med 1999; 246:489-495.
35. Leurs PB, Stolk RP, Hamulyak K, van Oerle R, Grobbee DE, Wolfenbuttel BHR. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 Diabetes. Diabetes Care 2002; 25:1340-1345.
36. Feskens EJ, Kromhout D. Hyperinsulinemia, risk factors, and coronary heart disease. The Zutphen Elderly Study. Arterioscler Thromb 1994; 14:1641-1647.
37. Carson SD. Tissue factor (coagulation factor III) inhibition by apolipoprotein A-II. J Biol Chem 1987; 262:718-721.
38. Noakes M, Clifton PM. Weight loss and plasma lipids. Curr Opin Lipidol 2000; 1:65-70.
39. Aubert H, Frere C, Aillaud MF, Morange PE, Juhan-Vague I, Alessi MC. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 2003; 1:791-797.
40. Leyva F, Godsland IF, Worthington M, Walton C, Stevenson JC. Factors of the metabolic syndrome. Baseline interrelationships in the first follow-up cohort of the HDDRISC Study (HDDRISC-1). Arterioscler Thromb Vasc Biol 1997; 18:208-214.
41. Godsland IF, Crook D, Proudler AJ, Stevenson JC. Hemostatic risk factors and insulin sensitivity, regional body fat distribution and the metabolic syndrome. J Clin Endocrinol Metabol 2005; 90:190-197.
42. Correia LC, Twickler MT, Sposito AC. Mechanistic insights and clinical relevance of the interaction between acute coronary syndromes and lipid metabolism. Semin Vasc Med 2004; 4:197-202.